Analysis Tools
normal phenotype
|
• mice have no overt phenotype and normal lifespans
|
|
Allele Symbol Allele Name Allele ID |
Brca1tm1Aash targeted mutation 1, Alan Ashworth MGI:3706167 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice have no overt phenotype and normal lifespans
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• some (2/59) develop salivary gland malignant myoepithelial tumors
|
|
• mice develop mammary gland tumors with higher frequency (64%; 25/39 animals) and shorter latency of 6-46 weeks (all but one tumor had developed by 31 weeks) relative to control mice; 6/39 mice had multiple tumors in the same and in adjacent glands
• tumors develop in the inguinal and thoracic glands with equal frequency, and on both sides of the body
• majority of tumors (30/33) show marked nuclear pleomorphism; central necrosis is seen in about 67% of tumors (23/32)
• most (29/33) neoplasms show mixed pushing and infiltrative borders, while only 4/33 showed a prominent inflammatory infiltrate
• most (29/33) tumors show homologous metaplastic elements in form of squamous or spindly differentiation
|
|
• high grade ductal carcinoma in situ (DCIS) is observed admixed with, or adjacent to, the invasive tumor in some cases, and occasionally columnar cell lesions with cytological atypia are seen with those tumors; columnar cell changes are found in adjacent tissue in a few tumors
|
|
• some (2/59) develop salivary gland malignant myoepithelial tumors
|
 |
• only 2/33 tumors show beta-catenin upregulation that was restricted to areas of squamous differentiation and basaloid cells
|
|
• mice develop mammary gland tumors with higher frequency (64%; 25/39 animals) and shorter latency of 6-46 weeks (all but one tumor had developed by 31 weeks) relative to control mice; 6/39 mice had multiple tumors in the same and in adjacent glands
• tumors develop in the inguinal and thoracic glands with equal frequency, and on both sides of the body
• majority of tumors (30/33) show marked nuclear pleomorphism; central necrosis is seen in about 67% of tumors (23/32)
• most (29/33) neoplasms show mixed pushing and infiltrative borders, while only 4/33 showed a prominent inflammatory infiltrate
• most (29/33) tumors show homologous metaplastic elements in form of squamous or spindly differentiation
|
|
• high grade ductal carcinoma in situ (DCIS) is observed admixed with, or adjacent to, the invasive tumor in some cases, and occasionally columnar cell lesions with cytological atypia are seen with those tumors; columnar cell changes are found in adjacent tissue in a few tumors
|
|
|
• only 2/33 tumors show beta-catenin upregulation that was restricted to areas of squamous differentiation and basaloid cells
|
|
• mice develop mammary gland tumors with higher frequency (64%; 25/39 animals) and shorter latency of 6-46 weeks (all but one tumor had developed by 31 weeks) relative to control mice; 6/39 mice had multiple tumors in the same and in adjacent glands
• tumors develop in the inguinal and thoracic glands with equal frequency, and on both sides of the body
• majority of tumors (30/33) show marked nuclear pleomorphism; central necrosis is seen in about 67% of tumors (23/32)
• most (29/33) neoplasms show mixed pushing and infiltrative borders, while only 4/33 showed a prominent inflammatory infiltrate
• most (29/33) tumors show homologous metaplastic elements in form of squamous or spindly differentiation
|
|
• high grade ductal carcinoma in situ (DCIS) is observed admixed with, or adjacent to, the invasive tumor in some cases, and occasionally columnar cell lesions with cytological atypia are seen with those tumors; columnar cell changes are found in adjacent tissue in a few tumors
|
|
• some (2/59) develop salivary gland malignant myoepithelial tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• some mice (which have not gone through pregnancies) develop salivary gland myoepithelial tumors
|
|
• mammary tumors occur in these control mice at lower frequency (12%: 5/43 animals) and much longer latency (12-15 months) compared to mice on a Trp43-haploinsufficient background
|
|
• mammary tumors occur in these control mice at lower frequency (12%: 5/43 animals) and much longer latency (12-15 months) compared to mice on a Trp43-haploinsufficient background
|
|
• some mice (which have not gone through pregnancies) develop salivary gland myoepithelial tumors
|
|
• mammary tumors occur in these control mice at lower frequency (12%: 5/43 animals) and much longer latency (12-15 months) compared to mice on a Trp43-haploinsufficient background
|
|
• some mice (which have not gone through pregnancies) develop salivary gland myoepithelial tumors
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| breast cancer | DOID:1612 |
OMIM:114480 |
J:119996 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/16/2024 MGI 6.23 |
|
|
|
||